脑梗死患者血小板活化状态的研究

目的了解脑梗死患者活化血小板分子标志物的改变,并探索预防和治疗脑梗死更为安全、有效的药物.方法应用流式细胞术,以单克隆抗体为分子探针,对正常对照组及脑梗死患者活化血小板分子标志物CD41a、CD62p进行检测,同时动态观察脑梗死患者应用阿司匹林联合硫酸氯吡格雷治疗前后CD41a、CD62p的变化.结果脑梗死患者血小板CD41a表达阳性率高于正常对照组,而CD62p表达阳性率无明显差别;其中脑梗死患者发病≤3d者CD41a表达阳性率较发病＞3d者增高.阿司匹林联合硫酸氯吡格雷治疗后脑梗死患者CD41a表达阳性率较单用阿司匹林者降低.结论脑梗死患者血小板活化程度明显增高,尤其是发病≤3d者;脑梗死患者应用阿司匹林联合硫酸氯吡格雷能使血小板活化受到更为明显、有效的抑制.

The research about the state of the activated blood platelet of cerebral infarction patients

Objective To detect the membrane glycoprotein markers of platelet activation in peripheral blood of patients with cerebral infarction, and to explore their clinical significance. Methods Two surface glycoproteins CD41a and CD62p on peripheral platelets were measured with flow cytometry both for patients with cerebral infarction and health subjects. CD41a and CD62p were also measured consecutively in patients receiving combined treatment of aspirin and clopidogrel. Results The positive rate of CD41a in patients with cerebral infarction was markedly higher than that of health subjects, but there was no significant difference in positive rate of CD62p between two groups. The positive rate of CD41a in the patients with disease onset less than 3 days was higher than those with onset more than 3 days. The positive rate of CD41a in patients receiving combination of aspirin with clopidogrel was lower than that of patients receiving aspirin alone. Conclusion As a marker for activated blood platelets, CD41a can be used to indicate the disease severity and treatment efficacy for patients with cerebral infarction.